10 days ago
Minutes from the Federal Reserve's September policy meeting reflect unanimous agreement among officials that interest rates needed to be higher to combat persistent inflation.
"Participants generally emphasized that inflation remained elevated while the labor market appeared to be near full employment, with some signs of strengthening, and that economic activity was expanding at a solid pace. Furthermore, almost all participants ****** sed that, while inflation risks were tilted to the upside, risks to the labor market had diminished and were now broadly balanced," minutes from the Sept. 16 meeting released Wednesday stated.
"Based on the outlook and the changing balance of risks, all participants viewed a higher target range for the federal funds rate as appropriate."
The Fed voted unanimously on Sept. 16 to raise rates, the first hike in three years. And at the time, most Federal Open Market Committee members saw a need for at least one more 25 basis point rate hike this year.
Markets were banking on a hike and expecting more to come.
#federal #hike #rates
"Participants generally emphasized that inflation remained elevated while the labor market appeared to be near full employment, with some signs of strengthening, and that economic activity was expanding at a solid pace. Furthermore, almost all participants ****** sed that, while inflation risks were tilted to the upside, risks to the labor market had diminished and were now broadly balanced," minutes from the Sept. 16 meeting released Wednesday stated.
"Based on the outlook and the changing balance of risks, all participants viewed a higher target range for the federal funds rate as appropriate."
The Fed voted unanimously on Sept. 16 to raise rates, the first hike in three years. And at the time, most Federal Open Market Committee members saw a need for at least one more 25 basis point rate hike this year.
Markets were banking on a hike and expecting more to come.
#federal #hike #rates
10 days ago
It's common for new investors to want to hit home runs in their first at-bats. That situation is arguably amplified at a time when major equity indexes are regularly hitting record highs.
With glamorous, high-octane growth stocks leading the charge, some market participants may be losing sight of the value of the singles-and-doubles approach to dividend investing. Those investors shouldn't ignore history. Though the percentage trended lower over the past decade due to the prominence of low-yield and non-dividend tech darlings, dividends accounted for about a third of the S&P 500's total returns over the past century.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ******* ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Most investors don't think in 100-year increments, and that's understandable, but when it comes to dividend investing, history and long-term perspectives matter. And the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) is a prime example of a dividend exchange-traded fund (ETF) with a compelling history for long-term investors.
Locked in a seemingly daily battle with the Vanguard Dividend Appreciation ETF for the ******* le of the largest dividend ETF, the $108 billion Schwab fund has a nearly unmatched track record. Two weeks shy of its 15th birthday, this ETF, which tracks the Dow Jones U.S. Dividend 100 Index, has returned 532% since its launch.
#investors
With glamorous, high-octane growth stocks leading the charge, some market participants may be losing sight of the value of the singles-and-doubles approach to dividend investing. Those investors shouldn't ignore history. Though the percentage trended lower over the past decade due to the prominence of low-yield and non-dividend tech darlings, dividends accounted for about a third of the S&P 500's total returns over the past century.
Missed AI's "Act 1"? Act 2 Could Be 14x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our ******* ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
Most investors don't think in 100-year increments, and that's understandable, but when it comes to dividend investing, history and long-term perspectives matter. And the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) is a prime example of a dividend exchange-traded fund (ETF) with a compelling history for long-term investors.
Locked in a seemingly daily battle with the Vanguard Dividend Appreciation ETF for the ******* le of the largest dividend ETF, the $108 billion Schwab fund has a nearly unmatched track record. Two weeks shy of its 15th birthday, this ETF, which tracks the Dow Jones U.S. Dividend 100 Index, has returned 532% since its launch.
#investors
12 days ago
It's clear that the Princess of Wales has entered her autumn style era. Now that October is upon us, the 44-year-old has embraced the seasonal change with a plethora of darker-toned items.
Last week, Kate hosted a secret tea party for Three Peaks Challenge participants and their families at Windsor Castle. The royal looked elegant in a chocolate brown-coloured belted dress by the famously English heritage label Burberry. The structured fit-and-flare silhouette offered a clean, monochromatic look.
A new item in Kate's wardrobe, the £1,760 tailored dress is cut in a fit-and-flare silhouette that's cinched in with a striking, gold twist-lock belt. It also has slip pockets, which Kate was spotted appearing to use at certain moments. The dress appears to be bespoke as the sleeves are three-quarter length, whereas the frock on the shelves featured capped sleeves.
The Princess of Wales hosted a very special tea party at Windsor Castle (@ Andrew Parsons / Kensington Palace)
A year earlier, Kate wore the very same dress, but in black. During the German State visit in 2025, the mother of three was pictured viewing exhibits from the Royal Collection relating to Germany in the Green Drawing Room at Windsor Castle, alongside her husband, Prince William.
#kate #castle #dress #hosted
Last week, Kate hosted a secret tea party for Three Peaks Challenge participants and their families at Windsor Castle. The royal looked elegant in a chocolate brown-coloured belted dress by the famously English heritage label Burberry. The structured fit-and-flare silhouette offered a clean, monochromatic look.
A new item in Kate's wardrobe, the £1,760 tailored dress is cut in a fit-and-flare silhouette that's cinched in with a striking, gold twist-lock belt. It also has slip pockets, which Kate was spotted appearing to use at certain moments. The dress appears to be bespoke as the sleeves are three-quarter length, whereas the frock on the shelves featured capped sleeves.
The Princess of Wales hosted a very special tea party at Windsor Castle (@ Andrew Parsons / Kensington Palace)
A year earlier, Kate wore the very same dress, but in black. During the German State visit in 2025, the mother of three was pictured viewing exhibits from the Royal Collection relating to Germany in the Green Drawing Room at Windsor Castle, alongside her husband, Prince William.
#kate #castle #dress #hosted
28 days ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
There's a lot we can't predict, like the outcome of the midterm elections, who will make it to the Super Bowl or whether Taylor Swift was actually hinting at a new album release in that Emmy's sketch. But when it comes to what our retirement looks like, we can certainly try.
Many retirement plans offer predictive tools that can help savers forecast their future balances, retirement readiness, income replacement rates and more. Participants, however, aren't happy with the options: J.D. Power's recent survey of digital experience satisfaction for retirement plans found that predictive tools were the lowest-performing attribute.
"The technology in the 401(k) is seriously behind what people are used to in their consumer life," said Fred Barstein, CEO of The Retirement Advisor University. When the underlying technology structure is old and **** bersome, it's hard for the tools to be as effective as they could be.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.
#tools #sign #upside #like
There's a lot we can't predict, like the outcome of the midterm elections, who will make it to the Super Bowl or whether Taylor Swift was actually hinting at a new album release in that Emmy's sketch. But when it comes to what our retirement looks like, we can certainly try.
Many retirement plans offer predictive tools that can help savers forecast their future balances, retirement readiness, income replacement rates and more. Participants, however, aren't happy with the options: J.D. Power's recent survey of digital experience satisfaction for retirement plans found that predictive tools were the lowest-performing attribute.
"The technology in the 401(k) is seriously behind what people are used to in their consumer life," said Fred Barstein, CEO of The Retirement Advisor University. When the underlying technology structure is old and **** bersome, it's hard for the tools to be as effective as they could be.
Sign up for The Daily Upside at no cost for premium **** ysis on all your favorite stocks.
#tools #sign #upside #like
28 days ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
A mind is a terrible thing to waste, but college is awfully expensive.
Depending on where someone goes to school, they can be left with a lot of debt — an albatross that can hang around their neck for decades. Among 401(k) plan participants in their 40s, those with student loan debt had median retirement account balances roughly 45% lower than those without, according to a new report from the Employee Benefit Research Institute.
The best option is to figure out scholarships, financial aid, debt timelines and what school makes financial sense before going to college. But that's not reality for many clients, leaving advisors to help fit student debt into a financial plan that balances both loans and savings. "The biggest mistake I see is treating student loans as an all-or-nothing problem," said Corinna Rose, a CFP with Bell Investment Advisors. "Many borrowers think they need to eliminate every dollar of debt before they can start investing."
Sign up for The Daily Upside at no cost for premium ******* ysis on all your favorite stocks.
#student #sign #many
A mind is a terrible thing to waste, but college is awfully expensive.
Depending on where someone goes to school, they can be left with a lot of debt — an albatross that can hang around their neck for decades. Among 401(k) plan participants in their 40s, those with student loan debt had median retirement account balances roughly 45% lower than those without, according to a new report from the Employee Benefit Research Institute.
The best option is to figure out scholarships, financial aid, debt timelines and what school makes financial sense before going to college. But that's not reality for many clients, leaving advisors to help fit student debt into a financial plan that balances both loans and savings. "The biggest mistake I see is treating student loans as an all-or-nothing problem," said Corinna Rose, a CFP with Bell Investment Advisors. "Many borrowers think they need to eliminate every dollar of debt before they can start investing."
Sign up for The Daily Upside at no cost for premium ******* ysis on all your favorite stocks.
#student #sign #many
30 days ago
Evommune, Inc. (NYSE:EVMN) announced on September 8 that EVO756 missed its primary endpoint in a randomized, double-blind, placebo-controlled Phase 2b trial involving 121 adults with moderate-to-severe atopic dermatitis. The primary measure was the percentage change from baseline in Eczema Area and Severity Index, or EASI, at week 12. No tested dose met the primary or secondary endpoints, and development in that indication will stop.
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
Evommune, Inc. (NYSE:EVMN) had already discontinued EVO756 for chronic spontaneous urticaria following a June trial failure. Development continues in migraine prevention. The setbacks place greater weight on EVO301, which has positive Phase 2a eczema data and a Phase 2b study planned for mid-2027.
Evommune, Inc. (NYSE:EVMN) has clinical evidence supporting its next eczema program. In February, the company reported that EVO301 met the primary endpoint in a randomized, double-blind, placebo-controlled Phase 2a trial involving 70 adults. Participants received two intravenous doses or placebo over a 12-week study.
Evommune, Inc. (NYSE:EVMN) reported a 55% EASI reduction with EVO301 versus 22% with placebo at week 12, a difference of 33 percentage points. The study met its prespecified Bayesian success criterion, and a separate conventional ****** ysis showed statistical significance at p
30 days ago
The Federal Reserve raised its benchmark interest rate by a quarter percentage point on Wednesday, the first increase since July 2023, with Fed Chair Kevin Warsh saying inflation has been "too high ... for too long."
The decision, reached by a unanimous 12-0 vote of the Federal Open Market Committee, brings the federal funds rate to a new target range of 3.75%–4%. The Fed's post-meeting statement pointed to persistent price pressures and a durable economy, declaring: "Inflation remains elevated. Today's policy action will support a timelier return to the Committee's 2 percent goal. The Committee will deliver price stability."
At a news conference following the decision, Warsh said the Fed needed to be confident "that underlying inflation is moving to our objective clearly and at sufficient speed," adding that the FOMC had determined "this standard has not been satisfied." He pointed to three converging factors — a robust labor market, inflation still running above target, and ongoing conflict in the Middle East — as driving the committee's unanimous vote.
The Dow Jones Industrial Average shed more than 400 points in afternoon trading following the Fed's move. The S&P 500 and the tech-heavy Nasdaq Composite also slumped.
Updated economic projections released Wednesday showed FOMC participants nudged their inflation forecasts higher. The median projection for headline PCE inflation this year rose to 3.7% and core PCE to 3.4%, each up 0.1 percentage point from the June forecast, the Fed said. Officials do not expect inflation to return to the 2% target until 2029. The median unemployment rate projection for 2026 fell to 4.1%, down from 4.3% in June, while the GDP growth outlook rose to 2.3% from 2.2%.
#federal #rate #committee
The decision, reached by a unanimous 12-0 vote of the Federal Open Market Committee, brings the federal funds rate to a new target range of 3.75%–4%. The Fed's post-meeting statement pointed to persistent price pressures and a durable economy, declaring: "Inflation remains elevated. Today's policy action will support a timelier return to the Committee's 2 percent goal. The Committee will deliver price stability."
At a news conference following the decision, Warsh said the Fed needed to be confident "that underlying inflation is moving to our objective clearly and at sufficient speed," adding that the FOMC had determined "this standard has not been satisfied." He pointed to three converging factors — a robust labor market, inflation still running above target, and ongoing conflict in the Middle East — as driving the committee's unanimous vote.
The Dow Jones Industrial Average shed more than 400 points in afternoon trading following the Fed's move. The S&P 500 and the tech-heavy Nasdaq Composite also slumped.
Updated economic projections released Wednesday showed FOMC participants nudged their inflation forecasts higher. The median projection for headline PCE inflation this year rose to 3.7% and core PCE to 3.4%, each up 0.1 percentage point from the June forecast, the Fed said. Officials do not expect inflation to return to the 2% target until 2029. The median unemployment rate projection for 2026 fell to 4.1%, down from 4.3% in June, while the GDP growth outlook rose to 2.3% from 2.2%.
#federal #rate #committee
1 month ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#vaccine #pfizer #NYSE
1 month ago
Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies' experimental Lyme disease vaccine candidate, and will now begin the official review.
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French biotech Valneva SE (NASDAQ:VALN), this represents the formal transition from years of clinical development into European regulatory review.
The application is based on the Phase 3 VALOR trial, a placebo-controlled, randomized study of 9,437 participants aged five and older from high-incidence Lyme disease locations in US, Canada, and Europe. Participants got four doses on a phased schedule: one at months 0, 2, and 5-9, followed by a fourth dosage around a year later, shortly before the start of the next Lyme season. Topline data released in March 2026 demonstrated efficacy of over 70% in reducing confirmed Lyme disease cases, with the vaccine generally tolerated and no safety issues detected. However, the statistical picture was less clean than the headline efficacy suggests. The first prespecified **** ysis, which served as the primary endpoint, showed 73.2% efficacy but failed the trial's predefined statistical criterion because the lower bound of the 95% confidence interval was 15.8%, below the required 20%. A second prespecified **** ysis showed 74.8% efficacy and did meet that threshold.
Valneva SE (NASDAQ:VALN), the smallest of the two partners, views the vaccine as a clean competitive setup. According to the company, PF-07307405 is the most advanced Lyme disease vaccine candidate currently in clinical development, a rare spot in the vaccine industry where new entrants often face competition from existing treatments. Under the terms of the 2020 partnership and license agreement, Pfizer Inc. (NYSE:PFE) will have exclusive rights to produce and commercialize the vaccine if it is approved, while Valneva SE (NASDAQ:VALN) will benefit as a development partner.
The institutional stance is very different between the two companies, reflecting their very different sizes. Pfizer Inc. (NYSE:PFE) is still a strong name in the institutional **** e, with hedge fund ownership stable at 83 funds in the second quarter of 2026, the same as the first quarter, reflecting its position as a large, diversified pharmaceutical holding, rather than a name driven by a specific pipeline event. Valneva SE (NASDAQ:VALN), however, has little hedge fund exposure, with only 4 funds holding a position in the second quarter, up from 1 in the first quarter, reflecting the continued lack of visibility of the smaller partner among institutional investors.
#disease
1 month ago
BECKLEY, WV (WVNS) - Volunteers have started planning for the return of the Beckley 5k and Half Marathon event.
Community groups get involved at Beckley's Kids Classic Festival
Members of Active Southern West Virginia have partnered with the Beckley-Raleigh County Chamber of Commerce to present the race.
Participants will start and finish at the Beckley Exhibition Coal Mine. Top place finishers could even walk away with a medal for their efforts! Organizers said all proceeds raised will go to a good cause.
"All the funds raised from this and other Active Southern West Virginia events help us to offer free community activities - things like workplace wellness, our kids' run club in schools," said Jenni Canterbury, Development Director with Active Southern West Virginia."
The half marathon is scheduled to kick off at 8:00 the morning of Saturday, September 26th, while the 5k will get started at 8:30 the same morning.
Those interested can go online for more details including information on how to register and how to get involved with volunteering on event day.
#beckley #southern
Community groups get involved at Beckley's Kids Classic Festival
Members of Active Southern West Virginia have partnered with the Beckley-Raleigh County Chamber of Commerce to present the race.
Participants will start and finish at the Beckley Exhibition Coal Mine. Top place finishers could even walk away with a medal for their efforts! Organizers said all proceeds raised will go to a good cause.
"All the funds raised from this and other Active Southern West Virginia events help us to offer free community activities - things like workplace wellness, our kids' run club in schools," said Jenni Canterbury, Development Director with Active Southern West Virginia."
The half marathon is scheduled to kick off at 8:00 the morning of Saturday, September 26th, while the 5k will get started at 8:30 the same morning.
Those interested can go online for more details including information on how to register and how to get involved with volunteering on event day.
#beckley #southern
1 month ago
Kalib Perry is officially cleared to play for Louisville football (for now) and will be able to play in Saturday's game against No. 16 SMU.
On Monday, Sept. 14, a Jefferson County judge granted the linebacker's motion to join a lawsuit that granted several other athletes a temporary restraining order on the NCAA's stay request in the Wisne v. NCAA case. The stay request deemed those who entered college in 2022 ineligible of receiving a fifth year under the NCAA's new 5-for-5 ruling. Cardinals cornerback Jabari Mack is also part of the TRO and had two tackles and two pass breakups in the season opener.
Perry missed the first two games but is listed on the Cards' 2026 roster. He and Mack announced plans to come back to Louisville under the new 5-for-5 rule Aug. 15. They were active participants during the latter stages of fall camp until the NCAA's stay request was granted Aug. 21. Mack wasn't affected, having been part of the initial TRO, while Perry was deemed ineligible.
"Pretty much every day, we just call over compliance," Louisville head football coach Jeff Brohm said Aug. 21. "They tell us what we can do and not do, and we roll with it. … If your guys are here, you'd like them to be able to practice and play. So we're hopeful that can happen."
Perry was granted a motion to join the local lawsuit and apply the TRO to his eligibility on Sept. 3 but the NCAA filed an emergency appeal, which was denied, and a regular appeal after. In response to Perry's motion, the NCAA stated Thursday that Perry's inclusion "raises complex legal and factual issues that are not part of the primary dispute before the Court." It cited the football player having entered the NFL draft, though he went undrafted, and participated in NFL minicamps with the San Francisco 49ers and Tennessee ******* ans. On Aug. 27, the ACC released a statement that banned players that "previously declared for an NFL, NBA or WNBA Draft, and did not appropriately withdraw consistent with NCAA requirements to retain eligibility."
#mack
On Monday, Sept. 14, a Jefferson County judge granted the linebacker's motion to join a lawsuit that granted several other athletes a temporary restraining order on the NCAA's stay request in the Wisne v. NCAA case. The stay request deemed those who entered college in 2022 ineligible of receiving a fifth year under the NCAA's new 5-for-5 ruling. Cardinals cornerback Jabari Mack is also part of the TRO and had two tackles and two pass breakups in the season opener.
Perry missed the first two games but is listed on the Cards' 2026 roster. He and Mack announced plans to come back to Louisville under the new 5-for-5 rule Aug. 15. They were active participants during the latter stages of fall camp until the NCAA's stay request was granted Aug. 21. Mack wasn't affected, having been part of the initial TRO, while Perry was deemed ineligible.
"Pretty much every day, we just call over compliance," Louisville head football coach Jeff Brohm said Aug. 21. "They tell us what we can do and not do, and we roll with it. … If your guys are here, you'd like them to be able to practice and play. So we're hopeful that can happen."
Perry was granted a motion to join the local lawsuit and apply the TRO to his eligibility on Sept. 3 but the NCAA filed an emergency appeal, which was denied, and a regular appeal after. In response to Perry's motion, the NCAA stated Thursday that Perry's inclusion "raises complex legal and factual issues that are not part of the primary dispute before the Court." It cited the football player having entered the NFL draft, though he went undrafted, and participated in NFL minicamps with the San Francisco 49ers and Tennessee ******* ans. On Aug. 27, the ACC released a statement that banned players that "previously declared for an NFL, NBA or WNBA Draft, and did not appropriately withdraw consistent with NCAA requirements to retain eligibility."
#mack
1 month ago
Washington Commanders LB K'Lavon Chaisson (knee), LB Odafe Oweh (calf) and DT Daron Payne (knee) were limited participants in practice Friday, Sept. 11, but are not listed on the Week 1 injury report. OG Nick Allegretti (calf), DT Javon Kinlaw (back), LB Jordan Magee (chest), QB Marcus Mariota (knee), DE Charles Omenihu (wrist) and TE Ben Sinnott (oblique) fully participated and are not on the injury report.
SOURCE: Commanders PR
This article originally appeared on USA TODAY: Week 1 injury report for Commanders
#injury #washington #odafe
SOURCE: Commanders PR
This article originally appeared on USA TODAY: Week 1 injury report for Commanders
#injury #washington #odafe
1 month ago
Pete Davidson marked the 25th anniversary of 9/11 by honoring the father he lost that day. The comedian joined 9/11 Day's UNIITE For Good campaign, turning grief into a call for kindness.
Davidson's father, Scott Davidson, died while responding to the attacks in New York City. This year, Pete encouraged Americans to remember the tragedy by reviving the spirit of unity that followed.
Davidson shared his story in a video for 9/11 Day. "He was a firefighter for Ladder 118, Engine 205 in Brooklyn Heights," he said. "My dad loved being a fireman, and he loved saving people," Davidson added. Scott died while responding to the attacks alongside fellow firefighters.
The Saturday Night Live alum explained why UNIITE For Good felt fitting this year. "9/11 is usually a tough day," Davidson said, according to the campaign. He explained that participants could perform a good deed and pass the idea along. The campaign then added those pledges to a nationwide map.
The goal was to cover the country with visible examples of people helping others. Davidson hoped the initiative could make an emotionally difficult anniversary feel slightly lighter. The campaign also focused on what happened after September 11. Communities came together and helped strangers despite their differences.
#davidson #uniite #anniversary #died
Davidson's father, Scott Davidson, died while responding to the attacks in New York City. This year, Pete encouraged Americans to remember the tragedy by reviving the spirit of unity that followed.
Davidson shared his story in a video for 9/11 Day. "He was a firefighter for Ladder 118, Engine 205 in Brooklyn Heights," he said. "My dad loved being a fireman, and he loved saving people," Davidson added. Scott died while responding to the attacks alongside fellow firefighters.
The Saturday Night Live alum explained why UNIITE For Good felt fitting this year. "9/11 is usually a tough day," Davidson said, according to the campaign. He explained that participants could perform a good deed and pass the idea along. The campaign then added those pledges to a nationwide map.
The goal was to cover the country with visible examples of people helping others. Davidson hoped the initiative could make an emotionally difficult anniversary feel slightly lighter. The campaign also focused on what happened after September 11. Communities came together and helped strangers despite their differences.
#davidson #uniite #anniversary #died
1 month ago
You can find original article here WealthManagement. Subscribe to our free daily WealthManagement newsletters.
Edelman Financial Engines is extending its retirement plan advisory and fiduciary capabilities to the small and mid-sized business market. While the firm has long served business owners through its workplace and wealth businesses, this service focuses on helping smaller business owners offer and manage retirement plans for their employees.
The firm has partnered with ADP for payroll, human capital management and retirement services. Edelman's will provide investment management, 3(38) investment management, plan consulting and personalized financial advice to plan participants. That includes providing one-on-one discretionary advisory services for individual employees.
Employees also gain unlimited access to Edelman's phone-based licensed advisors, who average 10 years of industry tenure, along with on-demand digital planning tools.
"EFE financial wellness and advisory services have been available to employees in eligible workplace retirement plans through the ADP platform since 2018," said Chris Magno, senior vice president and general manager of ADP Retirement Services, in a statement. "The new service expands that relationship by delivering a more comprehensive retirement solution purpose-built for small and mid-sized businesses, offered in combination with the full-service recordkeeping, payroll integration and plan administration capabilities of ADP."
#Services #management #wealthmanagement
Edelman Financial Engines is extending its retirement plan advisory and fiduciary capabilities to the small and mid-sized business market. While the firm has long served business owners through its workplace and wealth businesses, this service focuses on helping smaller business owners offer and manage retirement plans for their employees.
The firm has partnered with ADP for payroll, human capital management and retirement services. Edelman's will provide investment management, 3(38) investment management, plan consulting and personalized financial advice to plan participants. That includes providing one-on-one discretionary advisory services for individual employees.
Employees also gain unlimited access to Edelman's phone-based licensed advisors, who average 10 years of industry tenure, along with on-demand digital planning tools.
"EFE financial wellness and advisory services have been available to employees in eligible workplace retirement plans through the ADP platform since 2018," said Chris Magno, senior vice president and general manager of ADP Retirement Services, in a statement. "The new service expands that relationship by delivering a more comprehensive retirement solution purpose-built for small and mid-sized businesses, offered in combination with the full-service recordkeeping, payroll integration and plan administration capabilities of ADP."
#Services #management #wealthmanagement
1 month ago
Cornerback DJ Turner was added to the Bengals injury report on Thursday.
The team listed Turner as a limited participant due to a hamstring injury. Mid-week additions to the report can foreshadow a Sunday absence and the team's Friday report will show if there's reason to worry about Turner missing the matchup with the Buccaneers.
Defensive linemen Jonathan Allen and B.J. Hill took rest days on Thursday.
Wide receivers Ja'Marr Chase (knee) and Tee Higgins (foot) remained full participants and both players are on track to play in the opener. Head coach Zac Taylor was less certain about defensive end Shemar Stewart (knee), but he was also able to get in a full session for the second day in a row.
#turner #sunday
The team listed Turner as a limited participant due to a hamstring injury. Mid-week additions to the report can foreshadow a Sunday absence and the team's Friday report will show if there's reason to worry about Turner missing the matchup with the Buccaneers.
Defensive linemen Jonathan Allen and B.J. Hill took rest days on Thursday.
Wide receivers Ja'Marr Chase (knee) and Tee Higgins (foot) remained full participants and both players are on track to play in the opener. Head coach Zac Taylor was less certain about defensive end Shemar Stewart (knee), but he was also able to get in a full session for the second day in a row.
#turner #sunday
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
1 month ago
The Browns may have to make a change to their planned offensive line for Sunday's opener in Jacksonville.
Right guard Teven Jenkins missed Thursday's practice with a back injury. Jenkins, who played in every game and made four starts for Cleveland last season, was listed as limited after leaving Wednesday's practice early.
If Jenkins can't play, third-round pick Austin Barber will be in line to get the start against the Jaguars.
The Browns' injury report was otherwise unchanged from Wednesday. Center Parker Brailsford (thumb) and defensive tackle Maliek Collins (quad) were limited participants while linebacker Carson Schwesinger (shoulder) was a full participant for the second straight day.
#limited
Right guard Teven Jenkins missed Thursday's practice with a back injury. Jenkins, who played in every game and made four starts for Cleveland last season, was listed as limited after leaving Wednesday's practice early.
If Jenkins can't play, third-round pick Austin Barber will be in line to get the start against the Jaguars.
The Browns' injury report was otherwise unchanged from Wednesday. Center Parker Brailsford (thumb) and defensive tackle Maliek Collins (quad) were limited participants while linebacker Carson Schwesinger (shoulder) was a full participant for the second straight day.
#limited
0.00$ raised of 0.00$ goal
0 donations
0.00$
to go
1 month ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
Despite financial pressures, workers remain committed to their retirement goals, with many boosting their contribution rates — and watching their savings grow.
According to Fidelity Investments' latest quarterly ******* ysis, 769,000 retirement savers have a million dollars or more in their 401(k). Average 401(k) balances grew 10.5% in the second quarter, marking their strongest quarterly growth since the fourth quarter of 2020, thanks partly to stock market gains.
The total average savings rate also held at record levels for the second consecutive quarter, remaining at 14.4% for 401(k) savers and 12% for 403(b) participants.
At the same time, Fidelity data shows more savers tapped their accounts for cash to cover expenses: 19.5% of retirement savers had an outstanding 401(k) loan in the second quarter, up from 19.2% at the end of the first quarter. The share of workers who took a hardship withdrawal increased year over year to 3%.
#savers #second
Despite financial pressures, workers remain committed to their retirement goals, with many boosting their contribution rates — and watching their savings grow.
According to Fidelity Investments' latest quarterly ******* ysis, 769,000 retirement savers have a million dollars or more in their 401(k). Average 401(k) balances grew 10.5% in the second quarter, marking their strongest quarterly growth since the fourth quarter of 2020, thanks partly to stock market gains.
The total average savings rate also held at record levels for the second consecutive quarter, remaining at 14.4% for 401(k) savers and 12% for 403(b) participants.
At the same time, Fidelity data shows more savers tapped their accounts for cash to cover expenses: 19.5% of retirement savers had an outstanding 401(k) loan in the second quarter, up from 19.2% at the end of the first quarter. The share of workers who took a hardship withdrawal increased year over year to 3%.
#savers #second
1 month ago
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#phase
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#phase
1 month ago
It is one of the most frustrating puzzles for market participants — and it is happening right now. Stocks feel sluggish, choppy, and unable to make decisive upside progress. Even more significantly, many market leaders are gyrating in price regularly.
Here's the Invesco QQQ Trust (QQQ) over the past two months. While the market's main fear gauge, the CBOE Volatility Index ($VIX) is tied to the S&P 500 Index ($SPX), QQQ and SPY are more in sync now than ever. So this level of volatility in QQQ should translate to the VIX, at least a little.
How to Play SNPS Stock as Layoffs Hit Synopsys
Micron Stock More Than Tripled in 2026. Now Taiwan Strike Threat Could Shake the AI Boom.
Dear Adobe Stock Fans, Mark Your Calendars for September 10
#volatility #trust
Here's the Invesco QQQ Trust (QQQ) over the past two months. While the market's main fear gauge, the CBOE Volatility Index ($VIX) is tied to the S&P 500 Index ($SPX), QQQ and SPY are more in sync now than ever. So this level of volatility in QQQ should translate to the VIX, at least a little.
How to Play SNPS Stock as Layoffs Hit Synopsys
Micron Stock More Than Tripled in 2026. Now Taiwan Strike Threat Could Shake the AI Boom.
Dear Adobe Stock Fans, Mark Your Calendars for September 10
#volatility #trust
1 month ago
On Sept. 27, the Bayada Regatta — one of the world's largest and longest-running rowing competitions for people with disabilities — is to return to Pennsauken.
The race is scheduled to run from 9 a.m. to 3 p.m. at the Camden County Boathouse, located at 7050 N. Park Drive at Cooper River Park.Attendance and parking are free for spectators.
Participants train and practice with their local rowing club, then join together for the annual opportunity to showcase their skills. The race participants range from beginners to Paralympians, who all use adaptive boat equipment for the race.
More in SJ: Uncle Giuseppe's Marketplace set to make South Jersey debut next year
"When this regatta began four decades ago, it was the first rowing competition just for people with disabilities," said Bayada CEO Bryony Winn, who joined the nonprofit in March 2026.
#rowing
The race is scheduled to run from 9 a.m. to 3 p.m. at the Camden County Boathouse, located at 7050 N. Park Drive at Cooper River Park.Attendance and parking are free for spectators.
Participants train and practice with their local rowing club, then join together for the annual opportunity to showcase their skills. The race participants range from beginners to Paralympians, who all use adaptive boat equipment for the race.
More in SJ: Uncle Giuseppe's Marketplace set to make South Jersey debut next year
"When this regatta began four decades ago, it was the first rowing competition just for people with disabilities," said Bayada CEO Bryony Winn, who joined the nonprofit in March 2026.
#rowing
1 month ago
On August 5, Vaxcyte (NASDAQ:PCVX) reported second-quarter results that read less like a snapshot of today and more like a countdown to a verdict. The clinical-stage vaccine maker has no product on the market yet, but its three late-stage trials for its lead pneumococcal candidate are now fully enrolled, with the first major readout due before year-end. Add a net loss that nearly doubled and a boardroom that just brought in two vaccine-industry veterans, and you have a company betting its near-term story on data still to come.
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#opus #data
Vaxcyte's three Phase 3 studies of VAX-31, its next-generation pneumococcal conjugate vaccine, have dosed 6,191 adults combined, with roughly 3,500 of them receiving the actual candidate. The largest, OPUS-1, put 4,049 participants through head-to-head comparisons against Prevnar 20 and Capvaxive, the two shots VAX-31 needs to beat to earn a spot in the standard vaccination schedule. Data on safety, tolerability, and immune response from that trial are due in the fourth quarter of 2026, with results from OPUS-2 and OPUS-3 following in the first half of 2027.
A separate Phase 2 study testing VAX-31 in infants, covering both the primary immunization series and a booster dose, is on a similar timeline. In June, Vaxcyte also dosed the first participants in a Phase 1 study of VAX-A1, aimed at preventing disease from Group A Streptococcus, with topline data expected in the second half of 2027. As of June 30, cash and investments stood at $2.5 billion, up from $2.44 billion at the end of 2025, and the board added Dr. Moncef Slaoui, previously chief scientific advisor to Operation Warp Speed and a three-decade GSK veteran, alongside Dr. John Markels, the former president of Merck's global vaccines business.
None of that pipeline progress comes cheap. Vaxcyte's net loss for the quarter ended June 30 was $284.3 million, up from $166.6 million in the same period a year earlier, and the increase shows up on both sides of the ledger. R&D spending rose to $267.9 million from $194.2 million, driven by manufacturing work to prepare for a possible launch and by the cost of running three simultaneous Phase 3 trials at once. G&A expenses climbed too, to $34.9 million from $32 million, largely from adding headcount.
Because Vaxcyte has no approved product generating sales, every one of those dollars comes straight off the balance sheet. The calendar adds pressure of its own: even a clean OPUS-1 readout in the fourth quarter of 2026 still leaves the OPUS-2 and OPUS-3 results, plus a required manufacturing consistency study, sitting in the first half of 2027, pushing any license application and launch well beyond that. The newer VAX-A1 program is earlier still, with its second stage contingent on a safety board signing off on the first.
#opus #data
1 month ago
Pakistan's troubled England tour has taken another unexpected turn, with the Pakistan Cricket Board reportedly taking mobile phones belonging to members of the national team into its custody ahead of the third and final Test at Edgbaston.
According to Pakistani 365 News, the players' devices have been handed over to the PCB and will remain with the board until the conclusion of the final Test. The report did not reveal the identities of the players whose phones were taken, while the PCB has not publicly stated why the devices were placed in its custody.
The development has raised questions about the extent of the authorities' powers over players' personal devices, particularly regarding when phones can be seized, retained or accessed and what safeguards apply to private communications.
Mobile phones are already subject to strict restrictions in international cricket, particularly inside areas designated as restricted during matches.
Under the ICC's Player and Match Officials Area regulations, players and support staff are not permitted to possess or use mobile phones or other communication devices inside restricted areas, including dressing rooms, during an international match.
Players are expected to place their devices in secure storage before entering such areas. The primary purpose of these regulations is to protect the integrity of international matches and prevent unauthorised communication.
However, those match-day restrictions are separate from a situation in which a player's personal phone is retained for an extended period.
The ICC Anti-Corruption Code gives authorised anti-corruption officials considerably broader powers when a formal integrity investigation is underway.
Under the code, an authorised anti-corruption official can make a written demand requiring a participant to surrender a mobile device or allow investigators to copy or download information from it when there are reasonable grounds to believe the material could be relevant to an investigation.
The information potentially covered by such a request is wide-ranging. It can include telephone and internet records, text messages, WhatsApp conversations, photographs, videos, audio files and other electronically stored documents.
Participants can also be required to provide passwords or access codes needed by investigators to obtain the relevant material.
A failure to comply with a legitimate demand during an anti-corruption investigation can itself result in disciplinary action.
Despite the ICC's provisions, the reported decision by the PCB to take possession of the players' phones does not, by itself, establish that an anti-corruption investigation is taking place.
There has been no confirmation that the PCB's action in England is connected to an integrity investigation involving corruption, betting or match-fixing. No player has been publicly accused of an integrity offence either.
There is also a distinction between the ICC's jurisdic
According to Pakistani 365 News, the players' devices have been handed over to the PCB and will remain with the board until the conclusion of the final Test. The report did not reveal the identities of the players whose phones were taken, while the PCB has not publicly stated why the devices were placed in its custody.
The development has raised questions about the extent of the authorities' powers over players' personal devices, particularly regarding when phones can be seized, retained or accessed and what safeguards apply to private communications.
Mobile phones are already subject to strict restrictions in international cricket, particularly inside areas designated as restricted during matches.
Under the ICC's Player and Match Officials Area regulations, players and support staff are not permitted to possess or use mobile phones or other communication devices inside restricted areas, including dressing rooms, during an international match.
Players are expected to place their devices in secure storage before entering such areas. The primary purpose of these regulations is to protect the integrity of international matches and prevent unauthorised communication.
However, those match-day restrictions are separate from a situation in which a player's personal phone is retained for an extended period.
The ICC Anti-Corruption Code gives authorised anti-corruption officials considerably broader powers when a formal integrity investigation is underway.
Under the code, an authorised anti-corruption official can make a written demand requiring a participant to surrender a mobile device or allow investigators to copy or download information from it when there are reasonable grounds to believe the material could be relevant to an investigation.
The information potentially covered by such a request is wide-ranging. It can include telephone and internet records, text messages, WhatsApp conversations, photographs, videos, audio files and other electronically stored documents.
Participants can also be required to provide passwords or access codes needed by investigators to obtain the relevant material.
A failure to comply with a legitimate demand during an anti-corruption investigation can itself result in disciplinary action.
Despite the ICC's provisions, the reported decision by the PCB to take possession of the players' phones does not, by itself, establish that an anti-corruption investigation is taking place.
There has been no confirmation that the PCB's action in England is connected to an integrity investigation involving corruption, betting or match-fixing. No player has been publicly accused of an integrity offence either.
There is also a distinction between the ICC's jurisdic
1 month ago
A $500,000 balance yields just $20,000 annually at the 4% withdrawal rate, yet still surpasses the median 65+ retirement account balance of $103,202.
Traditional 401(k) withdrawals count as ordinary income and can trigger taxation on up to 85% of Social Security benefits, raising the real cost of each dollar withdrawn.
A paid-off home, a cash reserve of one to two years, and delaying Social Security to capture the roughly 8% annual benefit increase each do more for lifetime income than portfolio size alone.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
Half a million dollars in retirement savings may sound modest when headlines are full of seven-figure nest eggs. But measured against what real retirees have actually accumulated, it is a substantial sum. Vanguard's 2026 How America Saves report shows that for participants aged 65 and older, the median account balance was $103,202 in 2025, with an average of $330,186. Transamerica's most recent survey put median Baby Boomer household retirement savings at $270,000. So a reader sitting on $500,000 is ahead of the typical retiree. The real planning question is what that balance can actually deliver in monthly income once you factor in withdrawal math, taxes, and Medicare.
#Retirement
Traditional 401(k) withdrawals count as ordinary income and can trigger taxation on up to 85% of Social Security benefits, raising the real cost of each dollar withdrawn.
A paid-off home, a cash reserve of one to two years, and delaying Social Security to capture the roughly 8% annual benefit increase each do more for lifetime income than portfolio size alone.
Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor)
Half a million dollars in retirement savings may sound modest when headlines are full of seven-figure nest eggs. But measured against what real retirees have actually accumulated, it is a substantial sum. Vanguard's 2026 How America Saves report shows that for participants aged 65 and older, the median account balance was $103,202 in 2025, with an average of $330,186. Transamerica's most recent survey put median Baby Boomer household retirement savings at $270,000. So a reader sitting on $500,000 is ahead of the typical retiree. The real planning question is what that balance can actually deliver in monthly income once you factor in withdrawal math, taxes, and Medicare.
#Retirement
1 month ago
The keto diet may have surprising benefits for liver health, a new study suggests.
The research, published in the journal Cell Metabolism, studied 42 adults who had obesity, prediabetes and excess liver fat.
In a randomized clinical trial, the participants were ***** igned to three weight-loss diets – a low-carb ketogenic diet, a Mediterranean diet and a low-fat, mostly plant-based diet.
Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests
The keto diet's calories consisted of about 4% carbohydrates and 73% fat, according to the study. The Mediterranean diet provided about 50% of calories from carbohydrates and 35% from fat, while the low-fat diet provided about 70% of calories from carbohydrates and 15% from fat.
#liver
The research, published in the journal Cell Metabolism, studied 42 adults who had obesity, prediabetes and excess liver fat.
In a randomized clinical trial, the participants were ***** igned to three weight-loss diets – a low-carb ketogenic diet, a Mediterranean diet and a low-fat, mostly plant-based diet.
Secret To Weight Loss May Be Hiding In Your Gut, New Study Suggests
The keto diet's calories consisted of about 4% carbohydrates and 73% fat, according to the study. The Mediterranean diet provided about 50% of calories from carbohydrates and 35% from fat, while the low-fat diet provided about 70% of calories from carbohydrates and 15% from fat.
#liver
1 month ago
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
The U.S. ETF industry is pushing back against the Securities and Exchange Commission's (SEC) broad review of "novel ETFs."
ETF professionals argue an overly wide definition could slow product launches and undermine one of the market's biggest advantages, even as increasingly complex funds test the boundaries of the traditional ETF structure, per a Reuters report.
The SEC opened the review in June after delaying a wave of proposed prediction-market ETFs. Its request covers ETFs that invest in innovative ***** et classes or use unconventional strategies and asks whether existing rules adequately address investor protection, market integrity, and the registration process.
More than 20 industry participants submitted comments around the Aug. 31 deadline, with the docket showing submissions from Charles Schwab, Franklin Templeton, Jane Street, Cboe Global Markets, Grayscale Investments, 21Shares, Andreessen Horowitz and Kalshi.
#industry #finance #securities #june
The U.S. ETF industry is pushing back against the Securities and Exchange Commission's (SEC) broad review of "novel ETFs."
ETF professionals argue an overly wide definition could slow product launches and undermine one of the market's biggest advantages, even as increasingly complex funds test the boundaries of the traditional ETF structure, per a Reuters report.
The SEC opened the review in June after delaying a wave of proposed prediction-market ETFs. Its request covers ETFs that invest in innovative ***** et classes or use unconventional strategies and asks whether existing rules adequately address investor protection, market integrity, and the registration process.
More than 20 industry participants submitted comments around the Aug. 31 deadline, with the docket showing submissions from Charles Schwab, Franklin Templeton, Jane Street, Cboe Global Markets, Grayscale Investments, 21Shares, Andreessen Horowitz and Kalshi.
#industry #finance #securities #june
1 month ago
The draw for the league phase of this season's competition took place at UEFA headquarters in Nyon, Switzerland this morning with ****** nal's meeting with FC Barcelona being the standout tie.
The 18-team league phase came in last season and replaced the former group stage format. All participants compete within one league structure with the top four teams advancing to the quarter-finals. Teams that finish in fifth to 12th place will contest play-offs while the remaining clubs will be eliminated. As teams with high UEFA club co-efficient rankings, Chelsea and ****** nal entered the draw in Pot 1 while Manchester City found themselves in Pot 3 as a result of their inferior recent European record.
The draw determined that Chelsea will take on Paris Saint-Germain (home), OL Lyonnes (away), AS Roma (home), BK Häcken (away), Austria Vienna (home) and OH Leuven (away) while ****** nal will face OL Lyonnes (home), FC Barcelona (away), SL Benfica (home), Paris FC (away). HB Køge (home) and Inter Milan (away). Finally, Manchester City will play Paris Saint-Germain (home), FC Bayern Munich (away), Real Madrid (home), BK Häcken (away), Austria Vienna (home), Inter Milan (away).
Full match details will be published by UEFA in due course. The league phase will start on 22/23 September 2026 and will run until 16 December 2026.
#Paris
The 18-team league phase came in last season and replaced the former group stage format. All participants compete within one league structure with the top four teams advancing to the quarter-finals. Teams that finish in fifth to 12th place will contest play-offs while the remaining clubs will be eliminated. As teams with high UEFA club co-efficient rankings, Chelsea and ****** nal entered the draw in Pot 1 while Manchester City found themselves in Pot 3 as a result of their inferior recent European record.
The draw determined that Chelsea will take on Paris Saint-Germain (home), OL Lyonnes (away), AS Roma (home), BK Häcken (away), Austria Vienna (home) and OH Leuven (away) while ****** nal will face OL Lyonnes (home), FC Barcelona (away), SL Benfica (home), Paris FC (away). HB Køge (home) and Inter Milan (away). Finally, Manchester City will play Paris Saint-Germain (home), FC Bayern Munich (away), Real Madrid (home), BK Häcken (away), Austria Vienna (home), Inter Milan (away).
Full match details will be published by UEFA in due course. The league phase will start on 22/23 September 2026 and will run until 16 December 2026.
#Paris
1 month ago
Sands Capital, an investment management company, released its "Sands Capital Select Growth Fund" Q2 2026 investor letter. The letter can be downloaded here. Select Growth Fund targets U.S. businesses driving significant structural change through disruptive innovation. The fund returned 23.2% in the quarter, outperforming the Russell 1000 Growth Index's 16.7%. U.S. large-cap growth equities rebounded sharply, driven by improving corporate fundamentals and renewed investor confidence in AI, despite geopolitical uncertainties. However, the market's gains were narrow, concentrated among AI beneficiaries. The portfolio's success stemmed from strength in AI infrastructure holdings, especially memory and storage, supported by better pricing and tightening supply. As AI development advances, continuous demand for compute capacity is expected, prompting investments in memory, CPUs, AI chips, and semiconductor manufacturing to address emerging bottlenecks essential for scaling AI. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, Sands Capital Select Growth Fund highlighted Intercontinental Exchange, Inc. (NYSE:ICE), a US-based financial services company that provides technology, data, and market infrastructure to financial institutions, corporations, and government entities. On September 1, 2026, Intercontinental Exchange, Inc. (NYSE:ICE) closed at $159.60 per share. Over the past month, Intercontinental Exchange, Inc. (NYSE:ICE) returned 4.85%, while its shares have declined 10.30% in the last 52 weeks. Intercontinental Exchange, Inc. (NYSE:ICE) has a market capitalization of $89.6 billion, and its stock has traded within a 52-week range of $121.79 to $177.00.
Sands Capital Select Growth Fund stated the following regarding Intercontinental Exchange, Inc. (NYSE:ICE) in its Q2 2026 investor letter:
"Intercontinental Exchange, Inc. (NYSE:ICE) is one of the world's largest operators of financial exchanges and clearinghouses. Shares declined as investor concerns around AI disruption in ICE's Mortgage business and potential competition from perpetual futures contracts weighed on the stock. Much of the underperformance appears to reflect multiple compression rather than a weakening of fundamentals, which remain solid. In our view, the market is overestimating the risk that AI will displace ICE Mortgage. The business is not simply a workflow solution; it is a platform that connects lenders, data vendors, and other participants required to originate, sell, and service mortgages, while also serving as a system of record for a significant portion of the U.S. mortgage ecosystem. We also believe concerns around perpetual futures competition are overstated, as the structure of these products may limit their use in institutional hedging and risk management, particularly before accounting for liquidity. As such, we believe the recent sell-off more than discounts these risks."
#investor
In its second-quarter 2026 investor letter, Sands Capital Select Growth Fund highlighted Intercontinental Exchange, Inc. (NYSE:ICE), a US-based financial services company that provides technology, data, and market infrastructure to financial institutions, corporations, and government entities. On September 1, 2026, Intercontinental Exchange, Inc. (NYSE:ICE) closed at $159.60 per share. Over the past month, Intercontinental Exchange, Inc. (NYSE:ICE) returned 4.85%, while its shares have declined 10.30% in the last 52 weeks. Intercontinental Exchange, Inc. (NYSE:ICE) has a market capitalization of $89.6 billion, and its stock has traded within a 52-week range of $121.79 to $177.00.
Sands Capital Select Growth Fund stated the following regarding Intercontinental Exchange, Inc. (NYSE:ICE) in its Q2 2026 investor letter:
"Intercontinental Exchange, Inc. (NYSE:ICE) is one of the world's largest operators of financial exchanges and clearinghouses. Shares declined as investor concerns around AI disruption in ICE's Mortgage business and potential competition from perpetual futures contracts weighed on the stock. Much of the underperformance appears to reflect multiple compression rather than a weakening of fundamentals, which remain solid. In our view, the market is overestimating the risk that AI will displace ICE Mortgage. The business is not simply a workflow solution; it is a platform that connects lenders, data vendors, and other participants required to originate, sell, and service mortgages, while also serving as a system of record for a significant portion of the U.S. mortgage ecosystem. We also believe concerns around perpetual futures competition are overstated, as the structure of these products may limit their use in institutional hedging and risk management, particularly before accounting for liquidity. As such, we believe the recent sell-off more than discounts these risks."
#investor
1 month ago
There are a lot of things to say when talking about the Cleveland Browns.
Very old fans can reminisce about how the franchise was once one of the league's dynasties, led by the father of the modern NFL in head coach Paul Brown. But with their last NFL championship coming in 1964, those memories grow dimmer every year.
Those of us who are old, but not that old, can share tales of the teams of the 1980s, perennial playoff participants that reached the cusp of the Super Bowl three times under the franchise's last great head coach in Marty Schottenheimer and everyone's favorite quarterback in Bernie Kosar.
For today's fans, those teams may as well have played in the leather helmet era; it was so long ago. And while they have been able to cheer for some of the franchise's most legendary players like Joe Thomas, Nick Chubb, Myles Garrett, and Joel Bitonio, that has not always been a comfort once the game ended on another lost Sunday afternoon.
That is because, of all the things one could say about the Browns, the one thing they have not been able to say much since 1999 is that the team plays winning football.
#head
Very old fans can reminisce about how the franchise was once one of the league's dynasties, led by the father of the modern NFL in head coach Paul Brown. But with their last NFL championship coming in 1964, those memories grow dimmer every year.
Those of us who are old, but not that old, can share tales of the teams of the 1980s, perennial playoff participants that reached the cusp of the Super Bowl three times under the franchise's last great head coach in Marty Schottenheimer and everyone's favorite quarterback in Bernie Kosar.
For today's fans, those teams may as well have played in the leather helmet era; it was so long ago. And while they have been able to cheer for some of the franchise's most legendary players like Joe Thomas, Nick Chubb, Myles Garrett, and Joel Bitonio, that has not always been a comfort once the game ended on another lost Sunday afternoon.
That is because, of all the things one could say about the Browns, the one thing they have not been able to say much since 1999 is that the team plays winning football.
#head
1 month ago
Descartes Systems Group announced Tuesday that it has acquired Extensiv, a warehouse management and fulfillment tech provider, for $120 million. The deal follows Descartes' $100 million acquisition of Tai last week.
The acquisition was funded with cash on hand.
California-based Extensiv helps 3PLs with inventory management and order fulfillment. It uses AI tools to leverage its omnichannel data and enhance decision making for warehouse operators.
"3PLs are under constant pressure to fulfill faster, scale flexibly, and support the evolving needs of modern brands," said Mikel Richardson, general manager of ecommerce operations at Descartes. … "Extensiv strengthens that position by adding more participants, more contextually rich operational data and fulfillment intelligence to the Descartes Global Logistics Network."
Like the addition of Tai, a TMS provider to freight brokers, the Extensiv deal deepens Descartes' reach into the logistics services provider market. It also builds out its warehousing, inventory management and ecommerce fulfillment offerings.
#management
The acquisition was funded with cash on hand.
California-based Extensiv helps 3PLs with inventory management and order fulfillment. It uses AI tools to leverage its omnichannel data and enhance decision making for warehouse operators.
"3PLs are under constant pressure to fulfill faster, scale flexibly, and support the evolving needs of modern brands," said Mikel Richardson, general manager of ecommerce operations at Descartes. … "Extensiv strengthens that position by adding more participants, more contextually rich operational data and fulfillment intelligence to the Descartes Global Logistics Network."
Like the addition of Tai, a TMS provider to freight brokers, the Extensiv deal deepens Descartes' reach into the logistics services provider market. It also builds out its warehousing, inventory management and ecommerce fulfillment offerings.
#management
1 month ago
Summers Value Partners, a boutique investment firm, noted in its Q2 2026 investor update that The Summers Value Fund delivered strong results in the quarter, returning 41.7% net, outperforming the Russell 2000 Index ETF (IWM), which returned 21.4%, and the Russell 2000 Value Index ETF (IWN), which returned 17.1%. The letter can be downloaded here. The Fund experienced its best quarter since inception, achieving profitability on both long and short positions. Favorable market conditions, particularly in small-cap and healthcare stocks, led to attractive investment opportunities. The Fund maintained a cash position of approximately 13%. Also, check the fund's top five holdings to see its best picks in 2026.
In its second-quarter 2026 investor letter, The Summers Value Fund highlighted Consensus Cloud Solutions, Inc. (NASDAQ:CCSI). Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) is a leading information delivery services provider through a software-as-a-service platform. On August 31, 2026, Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) closed at $38.25 per share. Over the past month, Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) declined 0.65%, but its shares are up 44.39% over the past year. Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) has a market capitalization of $700.93 million.
The Summers Value Fund stated the following regarding Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) in its Q2 2026 investor letter:
Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) - $695 million market cap. Consensus Cloud Solutions is a leading provider of cloud-based fax services to the healthcare sector under its well-recognized eFax brand. Faxing remains an important means of communication in the healthcare ecosystem with billions of pages sent each year. Faxing, while a legacy technology, allows industry participants to communicate in a HIPAA-compliant manner. Many hospitals and clinics still rely on physical fax machines while Consensus' cloud-based service feels more like sending an email.
Consensus was a busted spin-off from J2 Global when we started buying shares two years ago. The stock had declined from $65 to a low of $12 following missed expectations and an accounting restatement. At its low, the stock traded at 2.5x GAAP earnings. We began building our position at $16, or 3.5x GAAP earnings. Despite selling legacy technology into an industry in secular decline, the company had several attributes we found appealing: high margins, low customer churn, and strong free cash flow generation. After years of a declining share price, investor expectations and sell-side coverage were almost non-existent, which helped create the mispricing..." (Click here to read the full text)
#solutions
In its second-quarter 2026 investor letter, The Summers Value Fund highlighted Consensus Cloud Solutions, Inc. (NASDAQ:CCSI). Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) is a leading information delivery services provider through a software-as-a-service platform. On August 31, 2026, Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) closed at $38.25 per share. Over the past month, Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) declined 0.65%, but its shares are up 44.39% over the past year. Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) has a market capitalization of $700.93 million.
The Summers Value Fund stated the following regarding Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) in its Q2 2026 investor letter:
Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) - $695 million market cap. Consensus Cloud Solutions is a leading provider of cloud-based fax services to the healthcare sector under its well-recognized eFax brand. Faxing remains an important means of communication in the healthcare ecosystem with billions of pages sent each year. Faxing, while a legacy technology, allows industry participants to communicate in a HIPAA-compliant manner. Many hospitals and clinics still rely on physical fax machines while Consensus' cloud-based service feels more like sending an email.
Consensus was a busted spin-off from J2 Global when we started buying shares two years ago. The stock had declined from $65 to a low of $12 following missed expectations and an accounting restatement. At its low, the stock traded at 2.5x GAAP earnings. We began building our position at $16, or 3.5x GAAP earnings. Despite selling legacy technology into an industry in secular decline, the company had several attributes we found appealing: high margins, low customer churn, and strong free cash flow generation. After years of a declining share price, investor expectations and sell-side coverage were almost non-existent, which helped create the mispricing..." (Click here to read the full text)
#solutions
